Alnylam Pharmaceuticalsvs.BioMarin Pharmaceutical
ALNY vs BMRN · both in Biotech & innovation, part of the Medicine, pharma & life science value chain: Innovation-driven biotech companies focused on novel treatment modalities.
Alnylam Pharmaceuticals is about 2.3× larger than BioMarin Pharmaceutical by market cap; Alnylam Pharmaceuticals trades at the lower P/E (37.6 vs 183.0); year to date, BioMarin Pharmaceutical leads (+9.5% vs −40.6%).
Side by side
| ALNY | BMRN | |
|---|---|---|
| Market cap | $30.4B | $13.4B |
| Price | $240.08 | $66.12 |
| Today | +1.7% | +1.6% |
| Return YTD | −40.6% | +9.5% |
| Return 1Y | −48.1% | +11.1% |
| P/E | 37.6 | 183.0 |
| P/S | 6.3 | 3.9 |
| P/B | 22.4 | 2.1 |
Data as of 2026-08-26 · updates daily after U.S. close
The two companies
Alnylam PharmaceuticalsALNY
Turns RNA interference into drugs, mostly for rare and cardiovascular disease.
Full ALNY profile →BioMarin PharmaceuticalBMRN
Rare genetic disorders define the company. It sells enzyme replacement therapies and Voxzogo for dwarfism, and has taken gene therapy into hemophilia.
Full BMRN profile →More ALNY & BMRN comparisons
Other head-to-heads in the Biotech & innovation segment.
See where ALNY and BMRN sit in the full Medicine, pharma & life science map: every segment from suppliers to end markets.Open the Life science value chain →